The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 1 µg/ml. Predicted molecular weight: 21 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.
FunctionEssential component of the retromer complex, a complex required to retrieve lysosomal enzyme receptors (IGF2R and M6PR) from endosomes to the trans-Golgi network. Also required to regulate transcytosis of the polymeric immunoglobulin receptor (pIgR-pIgA). Has low protein phosphatase activity towards a serine-phosphorylated peptide derived from IGF2R (in vitro).
Tissue specificityUbiquitous. Highly expressed in heart, lung, placenta, spleen, peripheral blood leukocytes, thymus, colon skeletal muscle, kidney and brain.
Vacuolar protein sorting 29 (yeast homolog) antibody
Vacuolar protein sorting 29 (yeast) antibody
Vacuolar protein sorting 29 homolog (S. cerevisiae) antibody
Vacuolar protein sorting 29 homolog antibody
Vacuolar protein sorting associated protein 29 antibody
Vacuolar protein sorting-associated protein 29 antibody
Vacuolar sorting protein VPS29/PEP11 antibody
Vesicle protein sorting 29 antibody
VPS 29 antibody
x 007 protein antibody
Anti-VPS29 antibody images
Western blot - VPS29 antibody (ab98929)
Anti-VPS29 antibody (ab98929) at 1 µg/ml + ACHN cell lysate at 10 µg
Predicted band size : 21 kDa
References for Anti-VPS29 antibody (ab98929)
This product has been referenced in:
Munsie LN et al. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. Hum Mol Genet24:1691-703 (2015).
Read more (PubMed: 25416282) »
Fuse A et al. VPS29-VPS35 intermediate of retromer is stable and may be involved in the retromer complex assembly process. FEBS Lett589:1430-6 (2015).
Read more (PubMed: 25937119) »